The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis.
Rupesh V AgrawalBjorn Kaijun BetzlerIlaria TestiSarakshi MahajanAniruddha Kishandutt AgarwalDinesh Visva GunasekeranDhananjay RajeKanika AggarwalSomasheila I MurthyMark WestcottSoon-Phaik CheePeter McCluskeySu Ling HoStephen TeohCimino LucaJyotirmay BiswasShishir NarainManisha AgarwalPadmamalini MahendradasMoncef KhairallahNicholas JonesCarl P HerbortKalpana BabuSoumayava BasuEster CarreñoRichard LeeHassan Al-DhibiBahram BodaghiAlessandro InvernizziDebra A GoldsteinTalin Barisani-AsenbauerJulio José González-LópezSofia AndroudiReema BansalBruttendu MoharanaSimona Degli EspostiAnastasia TasiopoulouSengal NadarajahMamta AgarwalSharanaya AbrahamRuchi ValaRamandeep SinghAman SharmaKusum SharmaManfred ZierhutOnn Min KonEmmett T CunninghamJohn H KempenQuan Dong NguyenCarlos PavesioVishali GuptaPublished in: Ocular immunology and inflammation (2020)
Purpose: Tubercular intermediate uveitis (TIU) and panuveitis (TBP) are difficult to manage because of limitations in diagnostic tools and lack of evidence-based treatment guidelines. The Collaborative Ocular Tuberculosis Study (COTS) analyzed treatment regimens and therapeutic outcomes in patients with TIU and TBP.Methods: Multicentre retrospective analysis.Results A total of 138 TIU and 309 TBP patients were included. A total of 382 subjects received antitubercular therapy (ATT) (n = 382/447; 85.4%) and 382 received corticosteroids (n = 382/447; 85.4%). Treatment failure was observed in 78 individuals (n = 78/447; 17.4%), occurring less frequently in patients receiving ATT (n = 66/382; 17.2%) compared to those who did not (n = 12/65; 18.5%). The study did not show any statistically significant therapeutic effect of ATT in patients with TIU and TBP.Conclusion Taking into account the limitations of the retrospective, non-randomized study design, resultant reliance on reported data records, and unequal size of the samples, the current study cannot provide conclusive evidence on the therapeutic benefit of ATT in TIU and TBP.
Keyphrases
- end stage renal disease
- chronic kidney disease
- mycobacterium tuberculosis
- clinical trial
- type diabetes
- randomized controlled trial
- metabolic syndrome
- mesenchymal stem cells
- double blind
- bone marrow
- open label
- electronic health record
- human immunodeficiency virus
- systemic lupus erythematosus
- cross sectional
- study protocol
- insulin resistance
- newly diagnosed
- skeletal muscle
- juvenile idiopathic arthritis
- ejection fraction
- patient reported outcomes
- smoking cessation
- cell therapy
- adverse drug
- drug induced
- patient reported